Skip to content
March 27, 2024

Equity.Guru

Investment information for the new generation

Search

drug delivery systems

The PCR test system demonstrated clinical accuracy in detecting SARS-CoV-2 RNA within 25 minutes, making it an ideal screening tool for international airports….
Xphyto Therapeutics (XPHY.C) subsidiary Xphyto Therapeutics entered into an agreement with Applied Pharmaceutical Innovation for the synthesis of pharma-grade psychedelic compounds and development of standard operating procedures to attract…
Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”….
Heritage Cannabis Holdings (CANN.C) signed into a supply agreement with IntelGenx (IGX.V) to manufacture and supply filmstrip products containing 10 mg of CBD for the Canadian and Australian markets,…
Pure Extracts Technologies (PULL.C) commenced a study on the formulation and manufacturing of psilocybin-based treatments today, according to a press release. The products will come as oral tablets, capsules…
On Thursday, December 17th, 2020 the Virtual Life Sciences Investor Forum (VLSIF) presents a six biotech companies….
Today’s federal election results could change the regulatory landscape in Oregon and Washington DC, as the residents of those states will vote to decide if psilocybin should be decriminalised….
Xphyto Therapeutics’ (XPHY.C) subsidiary Vektor Pharma TF GmbH has finished work on their oral disintegrating film (ODF), a dosage formulation for a major European pharma-company and is now ready…
Increased product efficacy and patient convenience is anticipated through faster onset of drug action, more predictable therapeutic activity and ease of use….
Xphyto and 3a are developing rapid screening tests for COVID-19 and other high-risk pandemic threats, including H1N1 (swine flu) and H5N1 (avian flu), with a specific focus on early…